People's Journal of Scientific Research
Published December 1, 2017 | Version v1
Journal article Open

Alteration of Serum Lipid Profile in Breast Cancer

Authors/Creators

  • 1. Department of Pathology, NKP Salve Institute of Medical Sciences & Research Centre, Nagpur

Description

The relationship between lipid levels and breast cancer in women has given conflicting results and is often debatable. The aim of this study was to analyze the role of variation in lipid profile in women developing breast cancer. Study was carried out between July 2014 to December 2015. Plasma lipids (i.e. Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides (TG) were analyzed from 85 controls and 85 breast cancer patients with clinical and histopathological evidence, Venous blood was withdrawn with aseptic precaution from the cases and controls and estimations of lipid profile were done. Data was analyzed by Epi Info Statical software. p value of <0.05 was taken as significant for all statistical analysis.A significant rise in serum total cholesterol, low-density lipoprotein and ratio of total cholesterol: high density lipoprotein values were found, whereas high density lipoprotein and very low density lipoprotein were not affected significantly by the breast cancer.

Files

17-22.pdf

Files (668.0 kB)

Name Size Download all
md5:58e0623494f0b175d1c70068bd721a50
668.0 kB Preview Download

Additional details

References

  • 1. Patel PS, Shah MH, Jha FP, et al.Alterations in plasma lipid pro-file patterns in head and neck cancer and oral precancerous conditions. Indian J Cancer. 2004; 41: 25-31.
  • 2. Halton JM, Nazir DJ, McQueen MJ, Barr RD. Blood lipid profiles in children with acute lymphoblastic leukemia. Cancer. 1998; 83: 379-84.
  • 3. Allampallam K, Dutt D, Nair C, et al. The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes' Hematother Stem Cell Res. 2000;9:247-55.
  • 4. Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, et al. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study. Nutr. Metab Cardiovasc. Dis 2010, 20, 41–48
  • 5. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer. 2006; 119:236-238
  • 6. MDRTC Lipid Measurement Fact Sheet. University of Michigan Health System. Retrieved October 8, 2009. http://www.med.umich.edu/mdrtc/cores/ Chem Core/lipids.htm
  • 7. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDLCholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med. 2007; 357:1301-10
  • 8. Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer 2006; 13:1033-67.
  • 9. Park SY, Kolonel LN, Henderson BE,Wilkens LR. Dietary fat and breast cancer in postmenopausal women according to ethnicity and hormone receptor status: The Multiethnic Cohort Study. Cancer Prev Res (Phila) 2012; 5:216-28.
  • 10 Rifai N, Warnick GR, McNamara JR, Belcher JD. Measurement of low density lipoprotein cholesterol in serum:Astatus report. Clin Chem. 1992; 38:150-60.
  • 11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma,without the use of preparative centrifuge. Clin Chem. 1972; 18:499-502.
  • 12. Barclay M, SkipskiVP. Lipoproteinins relation to cancer. Prog Biochem Pharmacol.1975;10:76-111.
  • 13. Rodriguez-Pinilla SM, Sarrio D, Honrado E, Hardisson D, CaleroF, Benitez J, et al. Prognostic significance of basallike phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res. 2006; 12:1533-9.
  • 14. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, EllisIO. Prognostic markers in triplenegative breast cancer. Cancer. 2007; 109:25-32.
  • 15. Florenza AM, Branchi A, Sommaviva D. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects.Int J Clin Lab Res. 2000;30:141-5.
  • 16. Paillasse MR, de Medina P, Amouroux G, Mhamdi L, Poirot M, Silvente-Poirot S. Signaling through cholesterol esterification: A new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. J Lipid Res 2009;50:2203-11.
  • 17. Yancey PG, Jerome GW, Yu H, Griffin EE, Cox BE, Babaev VR, etal. Severely altered cholesterol homeostasis in macrophages lacking apoE and SR-BI. J Lipid Res. 2007;48:1140-9.
  • 18. Hasija K, Bagga HK. Alterations of serum cholesterol and serum lipoprotein in breast cancer of women. Indian J Clin Biochem. 2005;20:61-6.
  • 19. Boekholdt MS, Thompson JF. Natural genetic variation as a tool in understanding the role of CETPin lipid levels and disease. J Lipid Res. 2003;44:1080- 93.
  • 20. Tornberg SA, Holm LE, Carstensen JM. Breast cancer risk in relation to serum cholesterol, serum beta lipoprotein, height, weight and blood pressure. Acta Oncol.1988;27:31-7.
  • 21. Ray G, Husain SA. Role of lipids, lipoproteins and vitamins in women with Breast cancer. Clin Biochem. 2001;34:71-6.
  • 22. Donegan WL, HartzAJ, RimmAA. The association of body weight with recurrent cancer of the breast. Cancer 1978, 41, 1590–1594.